Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Recorded on November 19, 2020
Morphology was once the only means of classifying blood cancers especially CLL; flow cytometry, cytogenetics and immunohistochemistry all followed. With a revolution in understanding, there is now a growing list of molecular tests that provide even more precise diagnostic and prognostic tools in diagnosis and treatment decisions. In this episode, Dr. Ken Miller speaks with Dr. Jennifer Brown from the Dana-Farber Cancer Institute about cancer genomics, its current applications in diagnosis, prognosis, treatment decisions, risk of recurrence, and the future of genomics testing in hematologic malignancies. Tune in to this informative conversation today!
Jennifer Brown, MD, PhD
Director, CLL Center
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Institute Physician
Dana-Farber Cancer Institute
Boston, MA
This podcast episode is supported by Foundation Medicine, Inc.
Podcast: Play in new window | Download (Duration: 33:20 — 30.5MB)